Kurt Lackovic

CEO at Cancer Trials Australia

Speaker

Dr Kurt Lackovic has built a career in medical research, spanning both academic and commercial settings.  He holds a PhD in chemistry, has completed international post-doctoral work in medical genomics and early-stage drug discovery, and earned an MBA from Melbourne Business School.  Kurt has published 26 peer-reviewed articles across diverse medical research areas and is a graduate of the Australian Institute of Company Directors. He is also an active member of the Licensing Executives Society of Australia and New Zealand, American Society of Clinical Oncology, Society for Clinical Research Sites and sits on AusBiotech’s Clinical Trials Advisory Group as well as the Research and Development Task Force.  As CEO of Cancer Trials Australia since 2017, Kurt has overseen the organisation’s significant growth, expanding its reach and impact within the Australian clinical trials landscape.  Beyond his role at CTA, Kurt also serves as a Director for both the Australian Physiotherapy Council and Deadly Science, where he also Chairs their Audit and Risk sub-committees.